Viking Therapeutics

Yahoo Finance • 3 hours ago

1 Reason This Biotech Stock Could Triple Before Year-End

Key Points Viking Therepeutics' VK2735 candidate is a dark horse contender among GLP-1 weight loss drugs. If upcoming late-stage clinical trial results prove positive, Viking's value as a takeover target could rise exponentially. While ri... Full story

Yahoo Finance • 10 days ago

Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity Drug

Eli Lilly reported study results Thursday that confirmed the "superior weight loss profile" of its next-gen obesity drug, retatrutide. Continue Reading... Full story

Yahoo Finance • 10 days ago

Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage Trial

Eli Lilly reported its experimental drug retatrutide delivered stronger weight loss than current treatments. Continue Reading... Full story

Yahoo Finance • 11 days ago

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics

Key Points Eli Lilly is the leader in the U.S. weight loss drug market, with a 60% share. Viking aims to enter this market -- and so far, its clinical trial results have been strong.10 stocks we like better than Eli Lilly › Generally, wh... Full story

Yahoo Finance • 18 days ago

Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026

Shares in Vikinig Therapeutics(NASDAQ: VKTX) rose by 16.5% in February, according to data fromS&P Global Market Intelligence. The move helped the stock recover in 2026, and at the time of writing, it's only down by a low single-digit perce... Full story

Yahoo Finance • 19 days ago

Is Viking Therapeutics (VKTX) One of the Shorted Biotech Stocks to Invest in

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 12, Michael Ulz from Morgan Stanley reduced his price target on Viking Therapeutics Inc. (NASDAQ:VKTX) from $... Full story

Yahoo Finance • last month

Viking Therapeutics, Inc. (VKTX): A Bull Case Theory

We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was trading at $29.30 as... Full story

Yahoo Finance • last month

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.

Key Points Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could soar if it can pass the upcoming clinical and regulatory hurdles.10 stocks we l... Full story

Yahoo Finance • last month

Why Viking Therapeutics Stock Is Up More Than 9% Today

Key Points Novo Nordisk’s weight-loss drug CagriSema failed to meet a critical goal in late-stage clinical trials. This shortcoming bodes well for pharmaceutical companies working on similar obesity treatments. Although Novo’s disappointi... Full story

Yahoo Finance • last month

Is Viking Therapeutics Stock Really Going to $125?

Key Points Viking Therapeutics is nearly done developing and testing a potential GLP-1 weight loss drug. While the company is still losing money, the underlying business appears solid. As is usual for biopharma stocks, this one is high-ri... Full story

Yahoo Finance • last month

Stock Indexes Under Pressure as Megacap Tech Stocks Fall

The S&P 500 Index ($SPX) (SPY) today is down -0.52%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.07%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.08%.  March E-mini S&P futures (ESH26) are down -0.58%, and March E-mini... Full story

Yahoo Finance • last month

Stocks Mixed on Strength in Chipmakers and Weakness in Cisco Systems

The S&P 500 Index ($SPX) (SPY) today is up +0.20%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.32%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.10%.  March E-mini S&P futures (ESH26) are up +0.26%, and March E-mini Nasdaq... Full story

Yahoo Finance • last month

Stocks making the biggest moves premarket: Cisco, QuantumScape, Rollins, Fastly and more

Check out the companies making the biggest moves in premarket trading: Restaurant Brands — Shares gained 1.3% following the Burger King parent's beat on the top and bottom lines . Restaurant Brands reported fourth-quarter earnings of 96 ce... Full story

Yahoo Finance • last month

Viking To Advance Oral VK2735 Into Phase 3 Trial For Obesity In 3Q26; Stock Up Over 10%

(RTTNews) - Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported its fourth-quarter and full-year 2025 financial results and provided a corporate update. The c... Full story

Yahoo Finance • last month

Cisco Systems, Applovin, Viking: After-Hours Movers

Asking for a Trend Host Josh Lipton eyes several stocks making moves in after-hours trading, including Cisco Systems (CSCO), Applovin (APP), and Viking Therapeutics (VKTX). To watch more expert insights and analysis on the latest market a... Full story

Yahoo Finance • 2 months ago

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?

Key Points Demand for weight loss drugs is high, and analysts predict the market may reach nearly $100 billion in a few years. Eli Lilly dominates the GLP-1 market in the U.S.10 stocks we like better than Eli Lilly › Eli Lilly(NYSE: LLY)... Full story

Yahoo Finance • 2 months ago

Hims & Hers Health Stops Offering Wegovy Pill Knockoff Over FDA Crackdown

Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill. Continue Reading... Full story

Yahoo Finance • 2 months ago

3 Things Investors Need to Know About the Healthcare Sector in 2026

Despite the last few years of remarkable advances in medicine, for investors considering buying healthcare stocks in 2026, this isn't a year to go on autopilot. Valuations of healthcare stocks aren't cheap, winning investments of yesteryea... Full story

Yahoo Finance • 2 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3 (Reuters) - Shares of obesity drugmakers and developers slid on Tuesday after Novo ​Nordisk forecast a sharper-than-expected sales decline ‌for 2026, underscoring intensifying competition in the blockbuster weight-loss market. Eli ‌... Full story

Yahoo Finance • 3 months ago

2 Beaten-Down Stocks That Could Bounce Back in 2026

Key Points Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges. 10 stocks we like better than Viking Therapeutics › One great way to earn above-average market returns is... Full story